scancell holdings plc (SCLP:London)
scancell holdings plc (SCLP) Snapshot
|
Open
38.00 GBp
|
Previous Close
38.00 GBp
|
|
|
Day High
43.50 GBp
|
Day Low
38.00 GBp
|
|
|
52 Week High
10/8/12 - 64.00 GBp
|
52 Week Low
06/11/12 - 7.75 GBp
|
|
|
Market Cap
84.1M
|
Average Volume 10 Days
201.3K
|
|
|
EPS TTM
-0.0060 GBp
|
Shares Outstanding
194.5M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
scancell holdings plc (SCLP) Related Businessweek News
No Related Businessweek News Foundscancell holdings plc (SCLP) Details
Scancell Holdings PLC operates as a biopharmaceutical company in the United Kingdom. The company, through its subsidiary, Scancell Limited, engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody and Moditope platforms. It develops SCIB1, a plasmid DNA vaccine, which is in phase II clinical trials for the treatment of melanoma; and SCIB2 that stimulates immune responses to the lung cancer antigen NY-ESO-1. The company has collaborations with Cancer Research Technology Limited; Immatics Biotechnologies GmbH; ImmuneRegen BioSciences, Inc; NIH; ImmunoVaccine Technologies; Ichor Medical Systems; and Merck KGaA. Scancell Holdings PLC is based in London, the United Kingdom.
Last Reported Date: 10/11/12
scancell holdings plc (SCLP) Top Compensated Officers
scancell holdings plc (SCLP) Key Developments
Scancell Holdings PLC announced that Peter Allen, ACA, has been appointed to the Board as Non-Executive Director, with immediate effect. More recently, as Chairman at Proximagen, Peter played a fundamental role in its acquisition by Upsher-Smith Laboratories for £357 million in 2012. Peter is currently Chairman of Clinigen PLC, Chroma Therapeutics Limited, ProStrakan plc and Future plc and a non-executive Director of Oxford Nanopore Technologies Limited.
Scancell Holdings PLC Presents at Sachs Associates Ltd.'s 6th Annual European Life Sciences CEO Forum, Mar-05-2013 through Mar-06-2013. Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Switzerland. Presentation Date & Speakers: Mar-05-2013, Richard Morley Goodfellow, Joint Chief Executive Officer and Director.
Scancell Holdings PLC announced that Michael Rippon, Non Executive Director, has resigned from the board of the Company with immediate effect.
| Recently Viewed | |||
| SCLP:LN | 43.25 GBp | +5.25 |  |
| Company | Last | Change | |
| No competitor information is available for SCLP. | |||
| View Industry Companies | |||
Industry Analysis
SCLP
Industry Average
| Valuation | SCLP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 13.0x |
|
| Price/Cash Flow | 149.5x |
|
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact SCANCELL HOLDINGS PLC, please visit www.scancell.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
